A new report from the World Economic Forum highlights a significant funding gap in women's health research, with only 20% of R&D investment directed towards conditions affecting women. This underfunding is concentrated in just a few areas like ovarian cancer and menopause, leaving other critical conditions like ischemic heart disease and premenstrual syndrome with minimal resources. The report, developed in collaboration with Kearney Health Institute, Gates Foundation, and Wellcome Leap, also points to a lack of women-specific clinical trials and a failure to translate scientific findings into scalable products, despite the potential to boost global GDP by $1 trillion annually. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Highlights systemic issues in health R&D funding and innovation, with potential implications for how digital tools and data analysis are applied in healthcare.
RANK_REASON The cluster reports on findings from a new research initiative and its implications for health R&D funding and policy. [lever_c_demoted from research: ic=1 ai=0.4]
